1,946 results match your criteria Journal of Ocular Pharmacology and Therapeutics[Journal]


Analog Derivatization of Cannabidiol for Improved Ocular Permeation.

J Ocul Pharmacol Ther 2019 Apr 18. Epub 2019 Apr 18.

1 Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, Oxford, Mississippi.

Cannabidiol (CBD), active component of plant , has anti-inflammatory properties that could potentially help treat diabetic retinopathy-induced pain and inflammation. However, CBD is a lipophilic molecule making its topical delivery to back of the eye challenging. This study aims at improving ocular penetration of CBD by means of analog derivatization. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.0141
Publisher Site
http://dx.doi.org/10.1089/jop.2018.0141DOI Listing
April 2019
4 Reads

Retinal Transcriptome Analysis in the Treatment of Endotoxin-Induced Uveitis with Tetramethylpyrazine Eye Drops.

J Ocul Pharmacol Ther 2019 Apr 17. Epub 2019 Apr 17.

1 The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing, China.

To investigate retinal gene expression of tetramethylpyrazine (TMP) eye drop-treated endotoxin-induced uveitis (EIU) in mice and to explore the mechanisms. The inflammatory signs of the anterior segment were evaluated, and clinical scores were graded. The retinal transcriptome from the TMP eye drop-treated and the untreated mice was identified by RNA sequencing (RNA-seq) strategy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0105DOI Listing

Eyes on New Product Development.

Authors:
Gary D Novack

J Ocul Pharmacol Ther 2019 Apr 17. Epub 2019 Apr 17.

1 PharmaLogic Development, Inc., San Rafael, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.29054.gdnDOI Listing

Benzalkonium Chloride Demonstrates Concentration-Dependent Antiviral Activity Against Adenovirus In Vitro.

J Ocul Pharmacol Ther 2019 Apr 10. Epub 2019 Apr 10.

The Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Purpose: Adenoviral conjunctivitis is the most common cause of conjunctivitis worldwide with no approved antiviral treatment. Benzalkonium chloride (BAK) is a common preservative in ophthalmic medications and is the active ingredient in some skin disinfectants and hand sanitizers. BAK is known to be effective in killing bacteria and enveloped viruses; however, its activity against ocular types of nonenveloped adenoviruses (Ads) is unknown. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.0145
Publisher Site
http://dx.doi.org/10.1089/jop.2018.0145DOI Listing
April 2019
2 Reads

Determination of a No Observable Effect Level for Endotoxin Following a Single Intravitreal Administration to Cynomolgus Monkeys.

J Ocul Pharmacol Ther 2019 Apr 9. Epub 2019 Apr 9.

1 Genentech, Inc., Department of Safety Assessment, South San Francisco, California.

Purpose: To characterize the inflammatory response and determine the no-observable-effect level (NOEL) in cynomolgus monkey eyes after intravitreal (ITV) injection of endotoxin.

Methods: The inflammatory response to endotoxin was assessed in a single-dose study in monkeys at doses of 0.01 to 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0149DOI Listing
April 2019
1 Read

Comparative Study Between Topical Gatifloxacin 0.5% and Moxifloxacin 0.5% as a Prophylactic Measure Before Intraocular Surgery.

J Ocul Pharmacol Ther 2019 Apr 5. Epub 2019 Apr 5.

1 Department of Ophthalmology, Fayoum University Faculty of Medicine, Fayoum, Egypt.

Purpose: To compare equal concentrations (0.5%) of moxifloxacin and gatifloxacin ophthalmic solutions with regard to conjunctival bacterial reduction as well as anterior chamber penetration.

Methods: One hundred patients were divided into 2 groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0088DOI Listing
April 2019
1 Read

Patient Preference-Based Comparative Effectiveness and Cost-Utility Analysis of the Prostamides for Open-Angle Glaucoma.

J Ocul Pharmacol Ther 2019 Apr 28;35(3):145-160. Epub 2019 Mar 28.

1 Center for Value-Based Medicine®, Hilton Head, South Carolina.

Purpose: To perform patient preference-based comparative effectiveness and cost-utility (cost-effectiveness) analyses to evaluate topical bimatoprost 0.01%, latanoprost 0.005%, travoprost 0. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.0114
Publisher Site
http://dx.doi.org/10.1089/jop.2018.0114DOI Listing
April 2019
5 Reads

Sustained Anti-Vascular Endothelial Growth Factor Activity of Aflibercept (Eylea) After Storage in Polycarbonate Syringes Used for Intravitreal Injection: A Pathway to Safety and Efficiency.

J Ocul Pharmacol Ther 2019 Mar 27. Epub 2019 Mar 27.

Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee, Wisconsin.

Purpose: Aflibercept (Eylea™, Regeneron) is supplied in single-use glass vials along with 1 cc polycarbonate syringes. We sought to determine if storage of aflibercept for sustained periods within these syringes would result in loss of antivascular endothelial growth factor (anti-VEGF) activity.

Methods: Aflibercept samples were drawn from commercially available glass vials into manufacturer-supplied 1-mL syringes and stored at 4°C. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0085DOI Listing

Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38.

J Ocul Pharmacol Ther 2019 Mar 23. Epub 2019 Mar 23.

4 Pharmaceutical R&D, Bausch + Lomb, Rochester, New York.

Purpose: To evaluate rheological properties, in vitro dissolution, and in vivo ocular pharmacokinetics of loteprednol etabonate (LE) (submicron) ophthalmic gel 0.38%.

Methods: The viscosity of the LE gel 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0136DOI Listing

Patient-Reported Nonadherence with Glaucoma Therapy.

J Ocul Pharmacol Ther 2019 Mar 21. Epub 2019 Mar 21.

1 Department of Ophthalmology, University Medical Center Mainz, Mainz, Germany.

Purpose: Effective glaucoma therapy relies to a great extent on the patients' ability to regularly self-administer eye drops. This study aimed to assess self-reported nonadherence and to identify potential barriers to adherence in glaucoma patients.

Methods: Participants completed a 16-item questionnaire, designed to examine nonadherence rate and assess the therapy experience. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0134DOI Listing

Outcome and Predictors for 2-Year Visual Acuity in Eyes with Diabetic Macular Edema Treated with Ranibizumab.

J Ocul Pharmacol Ther 2019 Mar 21. Epub 2019 Mar 21.

Department of Ophthalmology, Medical Faculty, Ondokuz Mayis University, Samsun, Turkey.

Purpose: To determine the role of baseline characteristics in predicting visual outcome in patients with diabetic macular edema (DME) treated with ranibizumab.

Methods: A review was carried out of the charts of 97 eyes that received pro re nata (PRN) intravitreal ranibizumab (IR) 0.5 mg treatment for DME. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0082DOI Listing

Eyes on New Product Development.

Authors:
Gary D Novack

J Ocul Pharmacol Ther 2019 Mar 21. Epub 2019 Mar 21.

1 PharmaLogic Development, Inc., San Rafael, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.29053.gdnDOI Listing

Evaluation of the Effects of Biohcly in an In Vivo Model of Mechanical Wounds in the Rabbit Cornea.

J Ocul Pharmacol Ther 2019 Apr 19;35(3):189-199. Epub 2019 Mar 19.

1 Department of Ophthalmology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China.

Purpose: Biohcly is a type of acidic nanoclustered water shown to exert an antimicrobial effect and play a role in the tissue-healing process in previous experiments. This study was performed to evaluate the in vivo effects of Biohcly treatment on mechanical corneal wound healing.

Methods: Rabbit cornea "acute" mechanical wounds were created with an 8-mm hydraulic pressure trephine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0098DOI Listing
April 2019
1.420 Impact Factor

GPR158 in the Visual System: Homeostatic Role in Regulation of Intraocular Pressure.

J Ocul Pharmacol Ther 2019 Mar 11. Epub 2019 Mar 11.

1 USC Institute for Genetic Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, California.

Purpose: GPR158 is a newly characterized family C G-protein-coupled receptor, previously identified in functional screens linked with biological stress, including one for susceptibility to ocular hypertension/glaucoma induced by glucocorticoid stress hormones. In this study, we investigated GPR158 function in the visual system.

Methods: Gene expression and protein immunolocalization analyses were performed in mouse and human brain and eye to identify tissues where GPR158 might function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0135DOI Listing
March 2019
1 Read

Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Pachychoroid Neovasculopathy.

J Ocul Pharmacol Ther 2019 Apr 26;35(3):174-181. Epub 2019 Feb 26.

Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research Institute, Konyang University College of Medicine, Seoul, South Korea.

Purpose: To compare the effectiveness of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment for pachychoroid neovasculopathy and neovascular age-related macular degeneration (AMD).

Methods: Twenty-two eyes with pachychoroid neovasculopathy and 183 eyes with neovascular AMD were retrospectively included for analysis. All patients were treatment naive and received an initial series of 3 monthly loading injections of anti-VEGF, followed by further injections as required. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0107DOI Listing
April 2019
1 Read

Eyes on New Product Development.

Authors:
Gary D Novack

J Ocul Pharmacol Ther 2019 Apr 20;35(3):137. Epub 2019 Feb 20.

1 PharmaLogic Development, Inc., San Rafael, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.29052.gdnDOI Listing

Evaluation of Antiglaucomatous Drops on Conjunctival Thickness in Patients with Primary Open-Angle Glaucoma.

J Ocul Pharmacol Ther 2019 Feb 13. Epub 2019 Feb 13.

Department of Ophthalmology, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey.

Purpose: To determine the effects of antiglaucomatous drops on the conjunctival thickness.

Methods: Between March 2018 and May 2018, conjunctival thicknesses (epithelium + stroma) were measured with anterior segment OCT in 51 eyes of the control group and 49 eyes who had glaucoma diagnosis at the Van YYU Medical Faculty Ophthalmology Department and had been using antiglaucomatous drops for at least 6 months. At 12 o'clock direction, horizontal multisections were taken aiming at the conjunctiva 3-5 mm away from the limbus. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.0124
Publisher Site
http://dx.doi.org/10.1089/jop.2018.0124DOI Listing
February 2019
3 Reads

Response to Chua et al. re: "The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study".

Authors:
Sang Wook Jin

J Ocul Pharmacol Ther 2019 Jan/Feb;35(1)

Division of Glaucoma, Department of Ophthalmology, Dong-A University College of Medicine, Busan, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.29050.resDOI Listing
January 2019

Linear Polyethylenimine-DNA Nanoconstruct for Corneal Gene Delivery.

J Ocul Pharmacol Ther 2019 Jan/Feb;35(1):23-31

1 Research Divison, Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri.

Purpose: This study investigated the efficiency and potential toxicity of a linear 22-kDa polyethylenimine (PEI)-DNA nanoconstruct for delivering genes to corneal cells and the effects of PEI nitrogen-to-DNA phosphate (N:P) ratio on gene transfer efficiency in vitro and in vivo.

Methods: A gel retardation assay, zeta potential measurement, bright-field microscopy, transfection with green fluorescent protein (GFP), immunofluorescence, and enzyme-linked immunosorbent assay (ELISA) were used to characterize the physicochemical and biological properties and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), lactate dehydrogenase (LDH), and reactive oxygen species (ROS) assay for cytotoxicity of the linear PEI-DNA nanoconstruct using in vitro cultured primary human corneal fibroblast and in vivo mouse models.

Results: Of the several evaluated N:P ratios, the highest gene transfection efficiency achieved without any notable cytotoxicity was observed at an N:P ratio of 30:1 (N:P 30). Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.0024
Publisher Site
http://dx.doi.org/10.1089/jop.2018.0024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354610PMC
February 2020
9 Reads
1.420 Impact Factor

Dose-Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure.

J Ocul Pharmacol Ther 2019 Apr 30;35(3):138-144. Epub 2019 Jan 30.

Allergan plc, Irvine, California.

Purpose: To compare the dose-response profiles of bimatoprost sustained-release implant (Bimatoprost SR) and topical bimatoprost in lowering intraocular pressure (IOP) in normotensive beagle dogs.

Methods: In 1 study, topical bimatoprost 0.001%, 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0095DOI Listing

Analgesic Effect of a Single Drop of Nepafenac 0.3% on Pain Associated with Intravitreal Injections: A Randomized Clinical Trial.

J Ocul Pharmacol Ther 2019 Apr 28;35(3):168-173. Epub 2019 Jan 28.

Department of Ophthalmology, Medical School, University of Patras, Patras, Greece.

Purpose: To evaluate the analgesic effect of nepafenac 0.3% in patients undergoing intravitreal injections (IVI) of antivascular endothelial growth factors.

Methods: This is a single-center, prospective, randomized, blinded, triple-arm, placebo-controlled interventional study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0113DOI Listing
April 2019
1 Read

Gene Therapy for Inherited Retinal Degeneration.

J Ocul Pharmacol Ther 2019 Mar 28;35(2):79-97. Epub 2019 Jan 28.

Department of Ophthalmology, USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.

Inherited retinal degeneration (IRD), a group of rare retinal diseases that primarily lead to the progressive loss of retinal photoreceptor cells, can be inherited in all modes of inheritance: autosomal dominant (AD), autosomal recessive (AR), X-linked (XL), and mitochondrial. Based on the pattern of inheritance of the dystrophy, retinal gene therapy has 2 main strategies. AR, XL, and AD IRDs with haploinsufficiency can be treated by inserting a functional copy of the gene using either viral or nonviral vectors (gene augmentation). Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.0087
Publisher Site
http://dx.doi.org/10.1089/jop.2018.0087DOI Listing
March 2019
5 Reads

Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States.

J Ocul Pharmacol Ther 2019 Apr 24;35(3):182-188. Epub 2019 Jan 24.

2 Clarity Pharma Research, LLC, Spartanburg, South Carolina.

Introduction: Repository corticotropin injection (RCI) has immune-modulatory and anti-inflammatory effects and is approved for multiple indications, including severe and acute chronic allergic and inflammatory processes involving the eye and adnexa. This study describes patient characteristics, treatment patterns, and physicians' assessments of patients with uveitis treated with RCI.

Methods: This was a retrospective medical record review of US patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0090DOI Listing
April 2019
5 Reads

Eyes on New Product Development.

Authors:
Gary D Novack

J Ocul Pharmacol Ther 2019 Mar 24;35(2):77-78. Epub 2019 Jan 24.

1 PharmaLogic Development, Inc., San Rafael, California.

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.29051.gdn
Publisher Site
http://dx.doi.org/10.1089/jop.2018.29051.gdnDOI Listing
March 2019
3 Reads

Conbercept and Ranibizumab Pretreatments in Vitrectomy with Silicone Oil Infusion for Severe Diabetic Retinopathy.

J Ocul Pharmacol Ther 2019 Apr 22;35(3):161-167. Epub 2019 Jan 22.

Department of Ophthalmology, The First Hospital of China Medical University, Shenyang, China.

Purpose: We compared the efficacies of intravitreal ranibizumab (IVR) and intravitreal conbercept (IVC) as the adjuvant pretreatments for vitrectomy with silicone oil infusion for tractional retinal detachment (TRD) secondary to proliferative diabetic retinopathy.

Methods: This retrospective study comprised 74 patients (79 eyes) who underwent vitrectomy with silicone oil tamponade for diabetic TRD. They received IVC (37 eyes) or IVR (42 eyes) at standard doses 3-5 days preoperatively and were followed up for ∼6 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0093DOI Listing
April 2019
4 Reads
1.420 Impact Factor

Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device.

J Ocul Pharmacol Ther 2019 Mar 7;35(2):124-131. Epub 2019 Jan 7.

3 Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California.

Purpose: We developed a polycaprolactone (PCL) co-delivery implant that achieves zero-order release of 2 ocular hypotensive agents, timolol maleate and brimonidine tartrate. We also demonstrate intraocular pressure (IOP)-lowering effects of the implant for 3 months in vivo.

Methods: Two PCL thin-film compartments were attached to form a V-shaped co-delivery device using film thicknesses of ∼40 and 20 μm for timolol and brimonidine compartments, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0096DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450452PMC
March 2019
27 Reads

Novel Triamcinolone Acetonide-Loaded Liposomes Topical Formulation for the Treatment of Cystoid Macular Edema After Cataract Surgery: A Pilot Study.

J Ocul Pharmacol Ther 2019 Mar 7;35(2):106-115. Epub 2019 Jan 7.

1 Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Zapopan, México.

Purpose: To report tolerability, safety, and efficacy of a topical triamcinolone acetonide-loaded liposomes formulation (TA-LF) in targeting the macular area in patients with refractory pseudophakic cystoid macular edema (PCME).

Methods: For tolerability, safety and efficacy evaluation, 12 eyes of 12 patients with refractory PCME were exposed to one drop of TA-LF (TA at 0.2%) every 2 h for 90 days or until best-corrected visual acuity (BCVA) was achieved. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0101DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450453PMC
March 2019
14 Reads

Celastrol Ameliorates Inflammation in Human Retinal Pigment Epithelial Cells by Suppressing NF-κB Signaling.

J Ocul Pharmacol Ther 2019 Mar 31;35(2):116-123. Epub 2018 Dec 31.

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, People's Republic of China.

Purpose: Celastrol is a triterpenoid quinine methide that exerts important biological effects on a variety of disease models. In this study, we aim to assess the ability of celastrol to inhibit lipopolysaccharide (LPS)-induced inflammation in retinal pigment epithelial (RPE) cells.

Methods: Primary cultures of human RPE (HRPE) cells and ARPE-19 cell lines were treated with celastrol alone or in combination with LPS. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.0092
Publisher Site
http://dx.doi.org/10.1089/jop.2018.0092DOI Listing
March 2019
12 Reads
1.420 Impact Factor

The In Vitro Evaluation of Povidone-Iodine Against Multiple Ocular Adenoviral Types.

J Ocul Pharmacol Ther 2019 Mar 27;35(2):132-136. Epub 2018 Dec 27.

The Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Purpose: Povidone-iodine (P-I) is being touted as a topical antiviral treatment for eye infections caused by adenovirus (Ad). This study evaluated the in vitro antiviral activity of the several P-I concentrations previously used in clinical studies against multiple ocular Ad types commonly associated with eye infections.

Methods: The antiviral activity of four concentrations of P-I was compared to vehicle for seven types of Ad after incubating the P-I with Ad at 33°C for various lengths of time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450451PMC
March 2019
1 Read

Eyes on New Product Development.

Authors:
Gary D Novack

J Ocul Pharmacol Ther 2019 Jan/Feb;35(1):1-2. Epub 2018 Dec 19.

1 PharmaLogic Development, Inc., San Rafael, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.29049.gdnDOI Listing
December 2018
1 Read

Pilot Study of the Safety and Tolerability of a Subconjunctival Penciclovir Implant in Cats Experimentally Infected with Herpesvirus.

J Ocul Pharmacol Ther 2019 Jan/Feb;35(1):38-49. Epub 2018 Dec 18.

1 Department of Surgical and Radiological Sciences, University of California-Davis, Davis, California.

Purpose: To assess safety and tolerability of a subconjunctival penciclovir implant in cats infected with feline herpesvirus type 1 (FHV-1).

Methods: Subconjunctival blank (n = 4 cats) or penciclovir-impregnated (n = 6) silicone implants were placed bilaterally in 10 normal, FHV-1-naive cats 7-8 days before viral inoculation. Outcomes included disease score, FHV-1 serology, conjunctival viral load, Schirmer tear tests (STT), tear film break-up times (TFBUTs), conjunctival histology, goblet cell density (GCD), body weight, tear and plasma penciclovir concentration, and corneal ulcer evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0043DOI Listing
December 2018
1 Read

In Vivo Choroidal Neovascularization and Macrophage Studies Provide Further Evidence for a Broad Role of Prostacyclin in Angiogenesis.

J Ocul Pharmacol Ther 2019 Mar 14;35(2):98-105. Epub 2018 Dec 14.

Department of Biological Sciences, Allergan, Inc. , Irvine, California.

Purpose: The purpose of these studies was (1) to investigate the ability of human M1 phenotype macrophages to secrete vascular endothelial growth factor (VEGF) and the influence of prostacyclin receptor (IP) stimulation (2) to evaluate the contribution of the proangiogenic prostanoid prostacyclin to experimental choroidal neovascularization Methods: Human macrophages derived from primary blood mononuclear cells were functionally biased toward the M1 phenotype by using tumor necrosis factor α (TNFα). Experimental choroidal neovascularization was produced by laser photocoagulation. Antagonist drugs RO-3244794 (IP antagonist) and GW 627368 (EP antagonist) were administered according to an optimal dosing regimen that was predetermined by bioavailability studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0077DOI Listing
March 2019
2 Reads

Preclinical Evaluation of a New Hydroxypropyl-Guar Phospholipid Nanoemulsion-Based Artificial Tear Formulation in Models of Corneal Epithelium.

J Ocul Pharmacol Ther 2019 Jan/Feb;35(1):32-37. Epub 2018 Nov 29.

Novartis Pharmaceuticals Corporation, Fort Worth, Texas.

Purpose: To evaluate the effect of hydroxypropyl-guar anionic phospholipid nanoemulsion (HP-guar nanoemulsion), a new artificial tear formulation for treatment of dry eye disease (DED), in corneal epithelium models.

Methods: Cultured human corneal epithelial cells were used to assess (1) hydration protection and hydration retention protection against desiccation, and (2) cell recovery after benzalkonium chloride (BAC) damage. Corneal epithelium permeability was measured by 5,6-carboxyfluorescein (CF) uptake in intact rabbit eyes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0031DOI Listing
November 2018
5 Reads

Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.

J Ocul Pharmacol Ther 2019 Jan/Feb;35(1):6-22. Epub 2018 Nov 8.

1 Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, Oxford, Mississippi.

Polyenes and azoles constitute 2 major drug classes in the antifungal armamentarium used to treat fungal infections of the eye such as fungal keratitis, endophthalmitis, conjunctivitis, and blepharitis. These classes of drugs have come to occupy an important niche in ophthalmic antifungal therapy due to their broad spectrum of activity against a variety of filamentous and yeast-like fungi. Natamycin suspension (Natacyn), a polyene antifungal drug, is currently the only US FDA-approved formulation for treating ophthalmic fungal infections, whereas the other polyene and azole antifungals such as amphotericin B, fluconazole, itraconazole, ketoconazole, miconazole, voriconazole, and posaconazole are routinely used off-label in the clinical setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0089DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354613PMC
November 2018
20 Reads

Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration.

J Ocul Pharmacol Ther 2018 Nov 9. Epub 2018 Nov 9.

8 Allergan plc , Irvine, California.

Purpose: To evaluate safety and efficacy of the vascular endothelial growth factor binding protein abicipar pegol (abicipar) versus ranibizumab for neovascular age-related macular degeneration.

Methods: Phase 2, multicenter, randomized, double-masked comparison (REACH study, stage 3). Patients (n = 64) received intravitreal injections of abicipar 1 mg or 2 mg at baseline, week 4, and week 8 (3 injections) or ranibizumab 0. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.0062
Publisher Site
http://dx.doi.org/10.1089/jop.2018.0062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306670PMC
November 2018
18 Reads

HMGB1 Antagonist, Box A, Reduces TLR4, RAGE, and Inflammatory Cytokines in the Cornea of P. aeruginosa-Infected Mice.

J Ocul Pharmacol Ther 2018 Nov 8. Epub 2018 Nov 8.

1 Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University School of Medicine , Detroit, Michigan.

Purpose: High mobility group box 1 (HMGB1) contributes to adverse disease outcome in Pseudomonas aeruginosa keratitis. This study tests Box A, an HMGB1 antagonist, in a model of the disease.

Methods: C57BL/6 mice (B6) were injected subconjunctivally (1 day before infection) with Box A or phosphate-buffered saline (PBS), infected with P. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.0073
Publisher Site
http://dx.doi.org/10.1089/jop.2018.0073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302910PMC
November 2018
7 Reads

Efficacy of Multiple Dexamethasone Intravitreal Implants for Refractory Retinal Vein Occlusion-Related Macular Edema and Effect of Prior Vitrectomy.

J Ocul Pharmacol Ther 2018 Nov 7. Epub 2018 Nov 7.

8 Vitreoretinal Division, Department of Ophthalmology, University Hospitals Leuven , Leuven, Belgium .

Purpose: To evaluate the efficacy of dexamethasone intravitreal implants (DEX implant) in patients with treatment-resistant macular edema (ME) owing to branch and central retinal vein occlusion (BRVO/CRVO), and the influence of prior vitrectomy on this treatment.

Methods: Multicenter retrospective chart review was performed on 40 CRVO and 32 BRVO eyes with persistent ME despite intravitreal anti-vascular endothelial growth factor agents and/or intravitreal triamcinolone, and/or laser therapy. Each patient received ≥1 dexamethasone 700 μg implant between March 2011 and December 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0012DOI Listing
November 2018
7 Reads

Fibrinolytic Capacity of Desmoteplase Compared to Tissue Plasminogen Activator in Rabbit Eyes.

J Ocul Pharmacol Ther 2019 Jan/Feb;35(1):66-75. Epub 2018 Oct 30.

1 Veterinary Ophthalmology, Equine Clinic, Vetsuisse Faculty Zurich, Zurich, Switzerland.

Purpose: Desmoteplase (DSPA) was evaluated and compared with tissue plasminogen activator (t-PA) for its intraocular fibrinolytic effect and short-term toxicity in an in vivo study using rabbit eyes.

Methods: Fibrin clots were induced in the anterior chamber of 44 rabbit eyes, and drug efficacy was measured by clot size reduction over 24 h. Topical DSPA eye drops (1. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.0070
Publisher Site
http://dx.doi.org/10.1089/jop.2018.0070DOI Listing
October 2018
14 Reads

Eyes on New Product Development.

Authors:
Gary D Novack

J Ocul Pharmacol Ther 2018 Oct 30. Epub 2018 Oct 30.

1 PharmaLogic Development, Inc. , San Rafael, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.29048.gdnDOI Listing
October 2018
1 Read

Eyes on New Product Development.

Authors:
Gary D Novack

J Ocul Pharmacol Ther 2018 Nov 26;34(9):603-604. Epub 2018 Oct 26.

1 PharmaLogic Development, Inc. , San Rafael, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.29047.gdnDOI Listing
November 2018
1 Read

Factors Affecting Relapse and Remission in Behçet's Uveitis Treated with Interferon Alpha2a.

J Ocul Pharmacol Ther 2019 Jan/Feb;35(1):58-65. Epub 2018 Oct 25.

2 Department of Internal Medicine, Division of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey.

Purpose: To investigate factors affecting relapse and remission in patients with Behçet uveitis (BU) in the context of using the interferon alpha2a (IFNα2a) therapy.

Methods: Clinical records were reviewed of 32 patients (totaling 54 eyes) presenting with severe BU who had been treated with IFNα2a therapy. Factors influencing relapsing-remitting course of BU during IFNα2a therapy and after the cessation of the agent were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0083DOI Listing
October 2018
10 Reads

Dose Optimization Based on Population Pharmacokinetic Modeling of High-Dose Cyclosporine, a P-glycoprotein Inhibitor, in Combination with Systemic Chemotherapy in Pediatric Patients with Retinoblastoma.

J Ocul Pharmacol Ther 2018 Nov 18;34(9):647-655. Epub 2018 Oct 18.

1 Graduate School of Clinical Health Sciences, Ewha Womans University , Seoul, Republic of Korea.

Purpose: Retinoblastoma is a childhood malignancy of the retina. To increase the exposures of systemic chemotherapy, high-dose cyclosporine, as a P-glycoprotein modulating agent, has been combined with a standard chemotherapy. However, the effective and safe dose of cyclosporine has not been well evaluated. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.0041
Publisher Site
http://dx.doi.org/10.1089/jop.2018.0041DOI Listing
November 2018
18 Reads

Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues.

J Ocul Pharmacol Ther 2019 Jan/Feb;35(1):50-57. Epub 2018 Oct 18.

1 Allergan plc, Irvine, California.

Purpose: To explore the ocular distribution of bimatoprost after intracameral administration of a biodegradable sustained-release bimatoprost implant (Bimatoprost SR) versus repeated topical administration of bimatoprost 0.03% ophthalmic solution in dogs. Bimatoprost SR and topical bimatoprost 0. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.0067
Publisher Site
http://dx.doi.org/10.1089/jop.2018.0067DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354606PMC
October 2018
2 Reads

Effect of Single Instillation of Two Hyaluronic Acid-Based Topical Lubricants on Tear Film Thickness in Patients with Dry Eye Syndrome.

J Ocul Pharmacol Ther 2018 Nov 16;34(9):605-611. Epub 2018 Oct 16.

1 Department of Clinical Pharmacology, Medical University of Vienna , Vienna, Austria .

Purpose: This study investigated the effect of single administration of 2 different hyaluronic acid-based topical lubricants on tear film thickness (TFT) in patients with moderate-to-severe dry eye disease (DED).

Methods: Sixty patients were randomized to receive eye drops containing unpreserved sodium hyaluronate, triglycerides, and phospholipids (HTP), unpreserved sodium hyaluronate (HA), or unpreserved sodium chloride (NaCl). TFT and lipid layer thickness (LLT) were assessed before and at defined time points after single instillation with a custom-built ultrahigh-resolution optical coherence tomography system and a white light interferometer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2018.0069DOI Listing
November 2018
1 Read

In Vitro Evaluation of Hybrid Cooperative Complexes of Hyaluronic Acid as a Potential New Ophthalmic Treatment.

J Ocul Pharmacol Ther 2018 Dec 16;34(10):677-684. Epub 2018 Oct 16.

1 Department of Experimental Medicine, School of Medicine, University of Campania "Luigi Vanvitelli ," Naples, Italy .

Purpose: The purpose of this in vitro study was to assess the potential benefits of eye drops based on hybrid cooperative complexes (HCCs) obtained from high and low molecular weight hyaluronic acid (HA).

Methods: Rheological measurements were performed to adjust the HCC concentration toward optimal resistance to drainage from the ocular surface. The viscosity and mucoadhesion profiles of the optimized preparation were derived. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.0046
Publisher Site
http://dx.doi.org/10.1089/jop.2018.0046DOI Listing
December 2018
4 Reads

Comparison of Ocular Surface Mucin Expression After Topical Ophthalmic Drug Administration in Dry Eye-Induced Mouse Model.

J Ocul Pharmacol Ther 2018 Nov 16;34(9):612-620. Epub 2018 Oct 16.

1 Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine , Seoul, Korea.

Purpose: To determine the mucinogenic effect of dry eye (DE) treatment drugs currently in use, we compared the levels of mucin production and inflammatory cytokine expression on the ocular surfaces using a DE-induced mice model.

Methods: C57BL/6 mice were separated into 6 groups: a control group, DE-induced mice with the vehicle and treated with cyclosporine A (CsA), rebamipide (Reb), diquafosol tetrasodium (DQS), or prednisolone (Pred). The mRNA expression of MUC 1, 4, 16, 5AC, and proinflammatory cytokines on the corneal epithelia were determined by quantitative real-time polymerase chain reaction. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.0005
Publisher Site
http://dx.doi.org/10.1089/jop.2018.0005DOI Listing
November 2018
4 Reads

A Novel Method to Eliminate Preservatives in Eye Drops.

J Ocul Pharmacol Ther 2018 Oct;34(8):584-589

5 Department of Ophthalmology and Visual Sciences, University of Louisville School of Medicine , Louisville, Kentucky.

Purpose: Multiuse eye drops must maintain sterility and typically accomplish this by added preservatives. However, preservatives often cause harmful side effects. A gauze barrier dressing ("BIOGUARD") recently cleared by the FDA has an immobilized poly diallyldimethylammonium chloride (p-DADMAC) coating and is an effective antimicrobial with minimal compound release into solution. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.0042
Publisher Site
http://dx.doi.org/10.1089/jop.2018.0042DOI Listing
October 2018
19 Reads

Assessing the Effects of Ripasudil, a Novel Rho Kinase Inhibitor, on Human Corneal Endothelial Cell Health.

J Ocul Pharmacol Ther 2018 Oct 12. Epub 2018 Oct 12.

1 Department of Ophthalmology and Visual Sciences, Carver College of Medicine, University of Iowa , Iowa City, Iowa.

Purpose: To determine how the Rho kinase inhibitor, ripasudil, affects metabolic function and cell viability in donor human corneal endothelial cells (HCECs).

Methods: Endothelial cell-Descemet membrane (EDM) tissues were treated with 10 μM ripasudil and assayed for mitochondrial and glycolytic activity using extracellular flux analysis and then compared to untreated controls. In addition, EDM tissues with a 24-h ripasudil treatment and control tissues were exposed to 1 μM staurosporine to induce apoptosis and then analyzed for cell viability using apoptosis and necrosis assays. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jop.2018.0063
Publisher Site
http://dx.doi.org/10.1089/jop.2018.0063DOI Listing
October 2018
3 Reads